Article Text

PDF
Treatment and management of children with haemolytic uraemic syndrome
  1. Patrick R Walsh1,2,
  2. Sally Johnson2,3
  1. 1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
  2. 2National Renal Complement Therapeutic Centre, Newcastle upon Tyne, UK
  3. 3Department of Paediatric Nephrology, Great North Children’s Hospital, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle upon Tyne, UK
  1. Correspondence to Dr Sally Johnson, Department of Paediatric Nephrology, Great North Children’s Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, NE1 4LP, UK; Sally.Johnson{at}nuth.nhs.uk

Abstract

Haemolytic uraemic syndrome (HUS), comprising microangiopathic haemolytic anaemia, thrombocytopaenia and acute kidney injury, remains the leading cause of paediatric intrinsic acute kidney injury, with peak incidence in children aged under 5 years. HUS most commonly occurs following infection with Shiga toxin-producing Escherichia coli (STEC-HUS). Additionally, HUS can occur as a result of inherited or acquired dysregulation of the alternative complement cascade (atypical HUS or aHUS) and in the setting of invasive pneumococcal infection. The field of HUS has been transformed by the discovery of the central role of complement in aHUS and the dawn of therapeutic complement inhibition. Herein, we address these three major forms of HUS in children, review the latest evidence for their treatment and discuss the management of STEC infection from presentation with bloody diarrhoea, through to development of fulminant HUS.

  • nephrology
  • haematology
  • general paediatrics
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors SJ devised the outline and overview for the article, provided regular supervision during the writing of the article and edited the final version. PRW performed literature review and appraisal and wrote the text of the article under supervision.

  • Competing interests SJ is a member of the scientific advisory board for the Alexion global aHUS Registry.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.